{"hands_on_practices": [{"introduction": "Understanding how a competitive antagonist works begins with its fundamental mechanism: a direct competition with the agonist for the same receptor binding site. This exercise guides you through the derivation of this interaction from first principles, using the Law of Mass Action. By modeling this molecular \"race,\" you will quantitatively predict the rightward shift in the agonist's dose-response curve, measured by the change in the half-maximal effective concentration ($EC_{50}$), and confirm why the maximal effect ($E_{\\max}$) remains unchanged in this classic scenario [@problem_id:4542832].", "problem": "A full agonist $A$ produces a response in a tissue where there are no spare receptors, and the transduction from occupancy to response is linear such that the response $E$ is proportional to the fraction of receptors occupied by $A$. The agonist binds reversibly to a single class of non-interacting receptors with Hill coefficient $n_{H}=1$. In the absence of any antagonist, the half-maximal effective concentration ($EC_{50,0}$) equals the agonist equilibrium dissociation constant $K_{A}$. A reversible competitive antagonist $B$ with equilibrium dissociation constant $K_{B}$ is added at a fixed concentration $[B]$. Assume the Law of Mass Action applies to both $A$ and $B$ binding to the same site, and that there are no allosteric effects.\n\nGiven $K_{B} = 10$ nM and $[B] = 30$ nM, use first principles of receptor occupancy at equilibrium to derive the apparent half-maximal effective concentration in the presence of antagonist, $EC_{50,\\mathrm{app}}$, in terms of $EC_{50,0}$, $K_{B}$, and $[B]$. Then compute the numerical value of the fold-shift $r \\equiv \\dfrac{EC_{50,\\mathrm{app}}}{EC_{50,0}}$ for the given $K_{B}$ and $[B]$. Finally, determine whether the maximum effect changes by calculating the ratio $\\rho \\equiv \\dfrac{E_{\\max,\\mathrm{app}}}{E_{\\max,0}}$ under these assumptions.\n\nProvide exact values; no rounding is required. Report your final answer as a row matrix with two entries $\\big(r,\\ \\rho\\big)$, both dimensionless numbers without units.", "solution": "The problem statement is assessed to be valid. It is scientifically grounded in the established principles of receptor pharmacology, specifically the model of reversible competitive antagonism. It is well-posed, with a complete and consistent set of definitions, assumptions, and data necessary to derive a unique solution. The language is objective and free of ambiguity.\n\nThe derivation begins from the first principles of receptor-ligand binding at equilibrium. Let $[R]$ be the concentration of free receptors, $[A]$ be the concentration of the agonist $A$, and $[B]$ be the concentration of the competitive antagonist $B$. The agonist and antagonist bind to the same receptor site.\n\nThe binding reactions are:\n$R + A \\rightleftharpoons RA$\n$R + B \\rightleftharpoons RB$\n\nThe equilibrium dissociation constants for the agonist ($K_A$) and antagonist ($K_B$) are defined by the Law of Mass Action:\n$$K_A = \\frac{[R][A]}{[RA]}$$\n$$K_B = \\frac{[R][B]}{[RB]}$$\n\nThe total concentration of receptors, $[R_T]$, is the sum of free receptors, agonist-bound receptors ($[RA]$), and antagonist-bound receptors ($[RB]$):\n$$[R_T] = [R] + [RA] + [RB]$$\n\nThe response $E$ is stated to be directly proportional to the fractional occupancy of receptors by the agonist, $p_A$. The fractional occupancy is defined as:\n$$p_A = \\frac{[RA]}{[R_T]}$$\n\nTo derive an expression for $p_A$, we first express $[R]$ and $[RB]$ in terms of $[RA]$ and constants. From the definition of $K_A$, we have $[R] = \\frac{K_A [RA]}{[A]}$. From the definition of $K_B$, we have $[RB] = \\frac{[R][B]}{K_B}$. Substituting the expression for $[R]$ into the expression for $[RB]$ yields:\n$$[RB] = \\frac{\\left(\\frac{K_A [RA]}{[A]}\\right)[B]}{K_B} = [RA]\\frac{K_A [B]}{K_B [A]}$$\n\nNow we substitute the expressions for $[R]$ and $[RB]$ into the total receptor conservation equation:\n$$[R_T] = \\frac{K_A [RA]}{[A]} + [RA] + [RA]\\frac{K_A [B]}{K_B [A]}$$\n\nFactoring out $[RA]$:\n$$[R_T] = [RA] \\left( 1 + \\frac{K_A}{[A]} + \\frac{K_A [B]}{K_B [A]} \\right)$$\n\nThe fractional occupancy $p_A$ is therefore:\n$$p_A = \\frac{[RA]}{[R_T]} = \\frac{1}{1 + \\frac{K_A}{[A]} + \\frac{K_A [B]}{K_B [A]}}$$\n\nTo simplify this expression, multiply the numerator and denominator by $[A]$:\n$$p_A = \\frac{[A]}{[A] + K_A + \\frac{K_A [B]}{K_B}}$$\n\nThis can be rearranged into a more standard form:\n$$p_A = \\frac{[A]}{K_A \\left(1 + \\frac{[B]}{K_B}\\right) + [A]}$$\n\nThe pharmacological response $E$ is proportional to $p_A$. Let $E_{\\max}$ be the maximum possible response, which occurs when $p_A = 1$. Given the linear transduction, we have $E = E_{\\max} \\cdot p_A$.\n$$E = E_{\\max} \\frac{[A]}{K_A \\left(1 + \\frac{[B]}{K_B}\\right) + [A]}$$\n\nIn the absence of the antagonist, $[B]=0$. The response is $E_0$:\n$$E_0 = E_{\\max,0} \\frac{[A]}{K_A + [A]}$$\nThe half-maximal effective concentration in the absence of antagonist, $EC_{50,0}$, is the concentration $[A]$ at which $E_0 = \\frac{1}{2} E_{\\max,0}$.\n$$\\frac{1}{2} E_{\\max,0} = E_{\\max,0} \\frac{EC_{50,0}}{K_A + EC_{50,0}} \\implies \\frac{1}{2} = \\frac{EC_{50,0}}{K_A + EC_{50,0}}$$\n$$K_A + EC_{50,0} = 2 \\cdot EC_{50,0} \\implies K_A = EC_{50,0}$$\nThis confirms the condition given in the problem statement.\n\nNow we determine the apparent maximum effect, $E_{\\max,\\mathrm{app}}$, in the presence of the antagonist. This is the limit of the response $E$ as $[A] \\rightarrow \\infty$:\n$$E_{\\max,\\mathrm{app}} = \\lim_{[A] \\to \\infty} E_{\\max} \\frac{[A]}{K_A \\left(1 + \\frac{[B]}{K_B}\\right) + [A]}$$\nDividing the numerator and denominator by $[A]$:\n$$E_{\\max,\\mathrm{app}} = E_{\\max} \\lim_{[A] \\to \\infty} \\frac{1}{\\frac{K_A}{[A]} \\left(1 + \\frac{[B]}{K_B}\\right) + 1} = E_{\\max} \\left(\\frac{1}{0 + 1}\\right) = E_{\\max}$$\nSince the intrinsic maximum response $E_{\\max}$ is a property of the agonist-receptor system, it is the same as $E_{\\max,0}$. Thus, $E_{\\max,\\mathrm{app}} = E_{\\max,0}$. A reversible competitive antagonist does not change the maximum effect. The ratio $\\rho$ is therefore:\n$$\\rho \\equiv \\frac{E_{\\max,\\mathrm{app}}}{E_{\\max,0}} = \\frac{E_{\\max,0}}{E_{\\max,0}} = 1$$\n\nNext, we derive the apparent half-maximal effective concentration, $EC_{50,\\mathrm{app}}$. This is the agonist concentration $[A]$ that produces half of the maximum response $E_{\\max,\\mathrm{app}}$ in the presence of the antagonist.\n$$E = \\frac{1}{2} E_{\\max,\\mathrm{app}} = \\frac{1}{2} E_{\\max}$$\nSubstituting this into the response equation with the antagonist:\n$$\\frac{1}{2} E_{\\max} = E_{\\max} \\frac{EC_{50,\\mathrm{app}}}{K_A \\left(1 + \\frac{[B]}{K_B}\\right) + EC_{50,\\mathrm{app}}}$$\n$$\\frac{1}{2} = \\frac{EC_{50,\\mathrm{app}}}{K_A \\left(1 + \\frac{[B]}{K_B}\\right) + EC_{50,\\mathrm{app}}}$$\n$$K_A \\left(1 + \\frac{[B]}{K_B}\\right) + EC_{50,\\mathrm{app}} = 2 \\cdot EC_{50,\\mathrm{app}}$$\n$$EC_{50,\\mathrm{app}} = K_A \\left(1 + \\frac{[B]}{K_B}\\right)$$\nSubstituting $EC_{50,0}$ for $K_A$, we obtain the desired expression:\n$$EC_{50,\\mathrm{app}} = EC_{50,0} \\left(1 + \\frac{[B]}{K_B}\\right)$$\nThis is a form of the Gaddum-Schild equation.\n\nThe fold-shift, $r$, is defined as the ratio $\\frac{EC_{50,\\mathrm{app}}}{EC_{50,0}}$.\n$$r \\equiv \\frac{EC_{50,\\mathrm{app}}}{EC_{50,0}} = \\frac{EC_{50,0} \\left(1 + \\frac{[B]}{K_B}\\right)}{EC_{50,0}} = 1 + \\frac{[B]}{K_B}$$\n\nWe are given $K_B = 10$ nM and $[B] = 30$ nM. We can now compute the numerical value of $r$. The units (nM) cancel out.\n$$r = 1 + \\frac{30}{10} = 1 + 3 = 4$$\n\nThe two dimensionless numbers required are $r = 4$ and $\\rho = 1$.", "answer": "$$\\boxed{\\begin{pmatrix} 4  1 \\end{pmatrix}}$$", "id": "4542832"}, {"introduction": "While theoretical derivations are crucial, pharmacology is an experimental science. This practice transitions from theory to application by using the Schild plot, a cornerstone of antagonist characterization. You will analyze a set of hypothetical experimental data to determine an antagonist's affinity ($K_B$) and, more importantly, to interpret what deviations from the ideal model tell us about the drug's mechanism of action [@problem_id:4935581]. This exercise highlights how quantitative analysis can reveal complexities beyond simple competitive antagonism.", "problem": "A reversible orthosteric antagonist is studied against a full agonist at a single receptor population under equilibrium conditions described by the law of mass action. Define the dose ratio $\\mathrm{DR}$ as the factor by which the agonist concentration required to elicit a fixed reference effect (for example, half-maximal effect) is increased in the presence of a fixed concentration of antagonist relative to control. Two experiments are conducted at antagonist concentrations $[B]_1$ and $[B]_2$, yielding dose ratios $\\mathrm{DR}_1$ and $\\mathrm{DR}_2$, respectively. Under the assumptions of competitive binding at the same site, no changes in agonist efficacy, and equilibrium conditions, construct the linear relationship used in Schild analysis by appropriately linearizing the relationship between $\\mathrm{DR}$ and $[B]$ with base-$10$ logarithms, then use the two data points to compute the line's slope and $y$-intercept.\n\nYou are given the following experimentally measured values, with antagonist concentrations expressed in molar units:\n- $[B]_1 = 1.0 \\times 10^{-8}\\,\\mathrm{M}$ with $\\mathrm{DR}_1 = 2.5$,\n- $[B]_2 = 1.0 \\times 10^{-7}\\,\\mathrm{M}$ with $\\mathrm{DR}_2 = 7.0$.\n\nUsing base-$10$ logarithms, compute:\n1. The Schild slope (the slope of the line obtained by plotting $\\log_{10}(\\mathrm{DR}-1)$ versus $\\log_{10}[B]$).\n2. The $y$-intercept of that line.\n\nBriefly interpret, in mechanistic terms, what a deviation of the Schild slope from $1$ would imply about the underlying pharmacological interaction, considering possibilities beyond ideal simple competitive antagonism. Your reasoning should begin from the definitions above and the equilibrium mass action framework.\n\nRound your final reported slope to four significant figures. Report only the Schild slope as your final numeric answer (unitless).", "solution": "The problem asks for the derivation of the Schild plot linear relationship, the calculation of its slope and intercept from given experimental data, and a mechanistic interpretation of a slope that deviates from the ideal value.\n\n**Step 1: Problem Validation**\n\nThe problem statement is first validated against the required criteria.\n\n*   **Extraction of Givens:**\n    *   A reversible orthosteric antagonist (denoted $B$) is studied against a full agonist (denoted $A$) at a single receptor population.\n    *   The system is assumed to be at equilibrium and follows the law of mass action.\n    *   Dose ratio, $\\mathrm{DR}$, is the factor by which the agonist concentration must be increased to achieve a fixed effect in the presence of the antagonist.\n    *   Experiment 1: Antagonist concentration $[B]_1 = 1.0 \\times 10^{-8}\\,\\mathrm{M}$ yields a dose ratio $\\mathrm{DR}_1 = 2.5$.\n    *   Experiment 2: Antagonist concentration $[B]_2 = 1.0 \\times 10^{-7}\\,\\mathrm{M}$ yields a dose ratio $\\mathrm{DR}_2 = 7.0$.\n    *   Core assumptions: simple competitive binding at the same orthosteric site, no change in agonist efficacy.\n    *   Task: Linearize the relationship between $\\mathrm{DR}$ and $[B]$ using base-$10$ logarithms to construct the Schild plot, compute the slope and $y$-intercept of the resulting line, and interpret deviations of the slope from unity.\n\n*   **Validation against Criteria:**\n    *   **Scientifically Grounded:** The problem is based on the well-established principles of receptor theory and Schild analysis, a fundamental method in pharmacology for quantifying antagonist affinity. This is scientifically sound.\n    *   **Well-Posed:** The problem provides two distinct data points, which uniquely define a straight line. The tasks of calculating the slope and intercept are mathematically straightforward. The request for interpretation is standard in this field.\n    *   **Objective:** The problem is stated with precise definitions and quantitative data, free from subjective or ambiguous language.\n    *   **Conclusion:** The problem is valid as it is scientifically sound, well-posed, and objective. There are no contradictions, missing information, or other flaws.\n\n**Step 2: Derivation of the Schild Equation**\n\nLet $A$ be the agonist, $B$ be the competitive antagonist, and $R$ be the receptor. The interactions are described by the following equilibrium reactions:\n$$A + R \\rightleftharpoons AR \\quad \\text{with dissociation constant} \\quad K_A = \\frac{[A][R]}{[AR]}$$\n$$B + R \\rightleftharpoons BR \\quad \\text{with dissociation constant} \\quad K_B = \\frac{[B][R]}{[BR]}$$\nThe total concentration of receptors, $[R]_T$, is the sum of free receptors $[R]$, agonist-bound receptors $[AR]$, and antagonist-bound receptors $[BR]$:\n$$[R]_T = [R] + [AR] + [BR]$$\nUsing the equilibrium constant definitions, we can express $[AR]$ and $[BR]$ in terms of $[R]$:\n$$[AR] = \\frac{[A][R]}{K_A} \\quad \\text{and} \\quad [BR] = \\frac{[B][R]}{K_B}$$\nSubstituting these into the total receptor equation:\n$$[R]_T = [R] + \\frac{[A][R]}{K_A} + \\frac{[B][R]}{K_B} = [R] \\left( 1 + \\frac{[A]}{K_A} + \\frac{[B]}{K_B} \\right)$$\nThe fractional occupancy of receptors by the agonist, $p_A$, which is proportional to the agonist-induced effect for a full agonist, is given by:\n$$p_A = \\frac{[AR]}{[R]_T} = \\frac{\\frac{[A][R]}{K_A}}{[R] \\left( 1 + \\frac{[A]}{K_A} + \\frac{[B]}{K_B} \\right)} = \\frac{\\frac{[A]}{K_A}}{1 + \\frac{[A]}{K_A} + \\frac{[B]}{K_B}}$$\nMultiplying the numerator and denominator by $K_A$ gives the standard form of the occupancy equation in the presence of a competitive antagonist:\n$$p_A = \\frac{[A]}{[A] + K_A \\left( 1 + \\frac{[B]}{K_B} \\right)}$$\nThe dose ratio, $\\mathrm{DR}$, is the ratio of the agonist concentration required to produce a given effect (i.e., a given $p_A$) in the presence of the antagonist ($[A]'$) to that in the absence of the antagonist ($[A]$).\nIn the absence of antagonist ($[B]=0$), the occupancy is $p_A = \\frac{[A]}{[A] + K_A}$.\nIn the presence of antagonist, the occupancy is $p_A = \\frac{[A]'}{[A]' + K_A \\left( 1 + \\frac{[B]}{K_B} \\right)}$.\nFor the effects to be equal, the occupancies must be equal. This implies that the term multiplying $K_A$ in the denominator must be constant for a given shift in the dose-response curve. More directly, the apparent agonist dissociation constant is increased by a factor of $\\left(1 + \\frac{[B]}{K_B}\\right)$. The dose ratio is this exact factor:\n$$\\mathrm{DR} = \\frac{[A]'}{[A]} = 1 + \\frac{[B]}{K_B}$$\nThis is the Gaddum-Schild equation.\n\n**Step 3: Linearization and Calculation**\n\nTo construct the linear relationship for a Schild plot, we rearrange the equation and take the base-$10$ logarithm:\n$$\\mathrm{DR} - 1 = \\frac{[B]}{K_B}$$\n$$\\log_{10}(\\mathrm{DR} - 1) = \\log_{10}\\left(\\frac{[B]}{K_B}\\right)$$\n$$\\log_{10}(\\mathrm{DR} - 1) = \\log_{10}[B] - \\log_{10}(K_B)$$\nThis equation is in the form of a straight line, $y = mx + c$, where:\n$y = \\log_{10}(\\mathrm{DR}-1)$\n$x = \\log_{10}[B]$\nThe theoretical slope $m$ is $1$. The theoretical $y$-intercept $c$ is $-\\log_{10}(K_B)$.\n\nWe now use the two given data points to compute the empirical slope and $y$-intercept.\n\nPoint 1: $[B]_1 = 1.0 \\times 10^{-8}\\,\\mathrm{M}$, $\\mathrm{DR}_1 = 2.5$.\n$x_1 = \\log_{10}([B]_1) = \\log_{10}(1.0 \\times 10^{-8}) = -8.0$\n$y_1 = \\log_{10}(\\mathrm{DR}_1 - 1) = \\log_{10}(2.5 - 1) = \\log_{10}(1.5)$\n\nPoint 2: $[B]_2 = 1.0 \\times 10^{-7}\\,\\mathrm{M}$, $\\mathrm{DR}_2 = 7.0$.\n$x_2 = \\log_{10}([B]_2) = \\log_{10}(1.0 \\times 10^{-7}) = -7.0$\n$y_2 = \\log_{10}(\\mathrm{DR}_2 - 1) = \\log_{10}(7.0 - 1) = \\log_{10}(6.0)$\n\nThe Schild slope ($m$) is calculated as:\n$$m = \\frac{y_2 - y_1}{x_2 - x_1} = \\frac{\\log_{10}(6.0) - \\log_{10}(1.5)}{-7.0 - (-8.0)} = \\frac{\\log_{10}\\left(\\frac{6.0}{1.5}\\right)}{1} = \\log_{10}(4.0)$$\nNumerically, the slope is:\n$m \\approx 0.60205999...$\nRounding to four significant figures, the Schild slope is $m = 0.6021$.\n\nThe $y$-intercept ($c$) can be calculated using the point-slope form of a line, $y - y_1 = m(x - x_1)$, with $x=0$:\n$$c = y_1 - m \\cdot x_1 = \\log_{10}(1.5) - (\\log_{10}(4.0))(-8.0) = \\log_{10}(1.5) + 8 \\log_{10}(4.0)$$\nNumerically, $c \\approx 0.17609 + 8(0.60206) \\approx 0.17609 + 4.81648 \\approx 4.99257$.\n\n**Step 4: Interpretation of Slope Deviation**\n\nThe theoretical slope for simple, reversible, competitive antagonism at a single receptor site is exactly $1$. The experimentally determined slope is approximately $0.6021$, which is a significant deviation from unity. In this context, the relationship is better described by the general form of the Schild equation:\n$$\\log_{10}(\\mathrm{DR}-1) = n \\cdot \\log_{10}[B] - \\log_{10}(K_B)$$\nwhere $n$ is the Schild slope. A slope other than $1$ indicates that the assumptions of ideal competitive antagonism are not met.\n\nA slope of $n1$, as observed here, can imply several mechanistic possibilities:\n1.  **Receptor Heterogeneity:** The antagonist may be binding to multiple receptor subtypes that have different affinities for it. This broadens the concentration-response relationship and leads to a shallower Schild plot slope.\n2.  **Insurmountable Antagonism:** The antagonism is not purely competitive. This can occur if the antagonist binds allosterically and reduces the efficacy of the agonist, or if it is \"pseudo-irreversible\" with a very slow dissociation rate from the receptor. In such cases, increasing agonist concentration cannot fully surmount the antagonism, violating a key principle of competitive interaction and resulting in a slope less than $1$.\n3.  **Non-Equilibrium Conditions:** The experiment may not have been run long enough for the antagonist to reach equilibrium with the receptors, especially if its dissociation rate is slow. This leads to an underestimation of antagonist potency, particularly at lower concentrations, which can depress the slope.\n4.  **Experimental Artifacts:** Factors such as antagonist uptake by transporters, sequestration by nonspecific binding sites (e.g., plasma proteins, lipids), or metabolism of the antagonist can reduce its free concentration at the receptor site, leading to an apparent slope of less than $1$.\n\nConversely, a slope of $n1$ is rare but could suggest positive cooperativity in antagonist binding or, more commonly, experimental artifacts such as antagonist sequestration which is more pronounced at lower concentrations. In this case, the calculated slope of approximately $0.6021$ strongly suggests that the interaction is more complex than simple competitive antagonism.", "answer": "$$\n\\boxed{0.6021}\n$$", "id": "4935581"}, {"introduction": "Not all antagonists compete for the same site. This practice explores the distinct effects of an irreversible, noncompetitive antagonist, which reduces the number of available receptors. Using the operational model of agonism, you will investigate how this reduction in receptors impacts both the agonist's apparent potency ($EC_{50}$) and its maximal effect ($E_{\\max}$). This exercise reveals the critical role of spare receptors, quantified by the transduction parameter $\\tau$, in a tissue's response and explains how a noncompetitive antagonist's effects can be masked or revealed depending on the system's underlying efficacy reserve [@problem_id:4935608].", "problem": "A full agonist binds to a receptor with equilibrium dissociation constant $K_{A}$ and produces a response in a biological system that exhibits spare receptors quantified by the transduction parameter $\\tau_{0}  0$. The agonistâ€™s effect arises from receptor occupancy governed by the law of mass action and a downstream stimulus-to-response transduction that converts occupancy into measurable effect. An irreversible, noncompetitive antagonist inactivates a fixed fraction of receptors without altering $K_{A}$ or downstream transduction efficiency per occupied receptor. The system initially has no antagonist present and then undergoes irreversible inactivation of $70\\%$ of receptors. Assume the transduction parameter $\\tau$ scales linearly with the fraction of available receptors.\n\nUsing only fundamental receptor occupancy under the law of mass action and a standard stimulus-to-response linkage in which the transduction parameter $\\tau$ represents the efficacy reserve, derive the following for the post-inactivation condition:\n\n1. The new apparent half-maximal effective concentration (EC50), denoted $\\mathrm{EC}_{50}'$, and the fold-change in apparent potency $\\mathrm{EC}_{50}'/\\mathrm{EC}_{50}$ expressed in terms of $\\tau_{0}$ and $K_{A}$.\n2. The new maximal response $E_{\\max}'$ relative to the original maximal response $E_{\\max}$ expressed as $E_{\\max}'/E_{\\max}$ in terms of $\\tau_{0}$.\n3. Determine whether the maximal response is halved by finding the value of $\\tau_{0}$ that satisfies $E_{\\max}'/E_{\\max} = \\frac{1}{2}$.\n\nTake the fraction of receptors remaining after inactivation to be $q = 1 - 0.7$. Express your final results as closed-form analytic expressions in terms of $\\tau_{0}$ and $K_{A}$ where appropriate. No rounding is required, and report all quantities as unitless ratios or exact algebraic values without units.", "solution": "The problem is valid as it is scientifically grounded in the principles of receptor pharmacology, is well-posed with a clear objective, and provides a complete and consistent set of assumptions. The solution requires the application of the operational model of agonism to derive the consequences of irreversible noncompetitive antagonism.\n\nThe relationship between agonist concentration $[A]$ and the biological response $E$ is described by a stimulus-response model. The stimulus, $S$, is generated by the binding of the agonist to its receptors, and the response is a function of this stimulus.\n\nFirst, receptor occupancy is governed by the law of mass action. The fraction of receptors occupied by the agonist is given by:\n$$ p_A = \\frac{[A]}{[A] + K_A} $$\nwhere $K_A$ is the equilibrium dissociation constant of the agonist.\n\nThe stimulus $S$ is proportional to the concentration of agonist-receptor complexes. Within the operational model framework, the stimulus is expressed using the transduction parameter $\\tau$, which encapsulates both receptor density and agonist efficacy:\n$$ S([A]) = \\tau \\cdot p_A = \\frac{\\tau [A]}{[A] + K_A} $$\n\nThe response $E$ is a hyperbolic function of the stimulus $S$. A common form for this relationship is:\n$$ E = \\frac{E_{\\text{sys}} S}{S + K_E} $$\nwhere $E_{\\text{sys}}$ is the maximal response of the tissue and $K_E$ is the stimulus that elicits a half-maximal response. For simplicity and without loss of generality when calculating ratios, we can normalize the response system by setting $E_{\\text{sys}} = 1$ and $K_E = 1$. This yields:\n$$ E(S) = \\frac{S}{S+1} $$\nSubstituting the expression for $S([A])$ into this response function gives the concentration-response relationship:\n$$ E([A]) = \\frac{\\frac{\\tau [A]}{[A] + K_A}}{\\frac{\\tau [A]}{[A] + K_A} + 1} = \\frac{\\tau [A]}{\\tau [A] + [A] + K_A} = \\frac{\\tau [A]}{(\\tau+1)[A] + K_A} $$\n\nFrom this fundamental equation, we derive expressions for the maximal response, $E_{\\max}$, and the half-maximal effective concentration, $\\mathrm{EC}_{50}$.\nThe maximal response $E_{\\max}$ is the limit as $[A] \\to \\infty$:\n$$ E_{\\max} = \\lim_{[A]\\to\\infty} \\frac{\\tau [A]}{(\\tau+1)[A] + K_A} = \\frac{\\tau}{\\tau+1} $$\nThe $\\mathrm{EC}_{50}$ is the concentration $[A]$ at which the response is half of the maximum, i.e., $E(\\mathrm{EC}_{50}) = E_{\\max}/2$:\n$$ \\frac{1}{2} E_{\\max} = \\frac{1}{2} \\frac{\\tau}{\\tau+1} $$\nSetting this equal to the response equation at $[A] = \\mathrm{EC}_{50}$:\n$$ \\frac{\\tau}{2(\\tau+1)} = \\frac{\\tau \\cdot \\mathrm{EC}_{50}}{(\\tau+1)\\mathrm{EC}_{50} + K_A} $$\n$$ (\\tau+1)\\mathrm{EC}_{50} + K_A = 2(\\tau+1)\\mathrm{EC}_{50} $$\n$$ K_A = (\\tau+1)\\mathrm{EC}_{50} \\implies \\mathrm{EC}_{50} = \\frac{K_A}{\\tau+1} $$\n\nInitially, with no antagonist, the system is described by the parameter $\\tau_0$. The initial maximal response and $\\mathrm{EC}_{50}$ are:\n$$ E_{\\max} = \\frac{\\tau_0}{\\tau_0+1} \\quad \\text{and} \\quad \\mathrm{EC}_{50} = \\frac{K_A}{\\tau_0+1} $$\n\nAfter inactivation, $70\\%$ of the receptors are removed, leaving a fraction $q = 1 - 0.7 = 0.3$ of receptors available. The problem states that the transduction parameter $\\tau$ scales linearly with the fraction of available receptors. Thus, the new transduction parameter, $\\tau'$, is:\n$$ \\tau' = q \\tau_0 = 0.3 \\tau_0 $$\nThe antagonist does not affect $K_A$. The new response parameters, $E_{\\max}'$ and $\\mathrm{EC}_{50}'$, are found by substituting $\\tau'$ into the general expressions:\n$$ E_{\\max}' = \\frac{\\tau'}{\\tau'+1} = \\frac{0.3\\tau_0}{0.3\\tau_0+1} $$\n$$ \\mathrm{EC}_{50}' = \\frac{K_A}{\\tau'+1} = \\frac{K_A}{0.3\\tau_0+1} $$\n\nWith these expressions, we can now address the three parts of the problem.\n\n1.  **New $\\mathrm{EC}_{50}'$ and fold-change in potency:**\n    The new apparent half-maximal effective concentration is $\\mathrm{EC}_{50}' = \\frac{K_A}{0.3\\tau_0+1}$.\n    The fold-change is the ratio $\\mathrm{EC}_{50}'/\\mathrm{EC}_{50}$:\n    $$ \\frac{\\mathrm{EC}_{50}'}{\\mathrm{EC}_{50}} = \\frac{\\frac{K_A}{0.3\\tau_0+1}}{\\frac{K_A}{\\tau_0+1}} = \\frac{\\tau_0+1}{0.3\\tau_0+1} $$\n\n2.  **New maximal response $E_{\\max}'$ relative to $E_{\\max}$:**\n    The ratio of the new maximal response to the original maximal response is $E_{\\max}'/E_{\\max}$:\n    $$ \\frac{E_{\\max}'}{E_{\\max}} = \\frac{\\frac{0.3\\tau_0}{0.3\\tau_0+1}}{\\frac{\\tau_0}{\\tau_0+1}} = \\frac{0.3\\tau_0(\\tau_0+1)}{\\tau_0(0.3\\tau_0+1)} = \\frac{0.3(\\tau_0+1)}{0.3\\tau_0+1} $$\n\n3.  **Value of $\\tau_0$ for which $E_{\\max}'/E_{\\max} = 1/2$:**\n    We set the expression from part 2 equal to $1/2$ and solve for $\\tau_0$:\n    $$ \\frac{0.3(\\tau_0+1)}{0.3\\tau_0+1} = \\frac{1}{2} $$\n    $$ 2 \\cdot 0.3(\\tau_0+1) = 0.3\\tau_0+1 $$\n    $$ 0.6\\tau_0 + 0.6 = 0.3\\tau_0+1 $$\n    $$ 0.6\\tau_0 - 0.3\\tau_0 = 1 - 0.6 $$\n    $$ 0.3\\tau_0 = 0.4 $$\n    $$ \\tau_0 = \\frac{0.4}{0.3} = \\frac{4}{3} $$\n\nThe three required results are the fold-change in $\\mathrm{EC}_{50}$, the ratio of maximal responses, and the specific value of $\\tau_0$.", "answer": "$$ \\boxed{ \\begin{pmatrix} \\frac{\\tau_0+1}{0.3\\tau_0+1}  \\frac{0.3(\\tau_0+1)}{0.3\\tau_0+1}  \\frac{4}{3} \\end{pmatrix} } $$", "id": "4935608"}]}